Evidence map›Paper›PMID 39773479›Full record

ArticleWorld journal of surgical oncology2025

SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment.

Sebastian Hoffmann, Tabea Hoffmann, Vlatko Potkrajcic, Christoph K W Deinzer, Katrin Benzler, Lars Zender, Adrien Daigeler, Johannes Tobias Thiel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sebastian HoffmannDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tuebingen, University of Tuebingen, Schnarrenbergstraße 95, Tuebingen, 72076, Germany.
Tabea HoffmannDepartment of Marketing, Faculty of Economics and Business, University Groningen, Groningen, The Netherlands.
Vlatko PotkrajcicDepartment of Radiation Oncology, University Hospital Tübingen, Hoppe-Seyler-Str. 3, Tuebingen, 72076, Germany.
Christoph K W DeinzerDepartment of Medical Oncology and Pneumology, University Hospital Tuebingen, Otfried-Mueller-Straße 10, Tuebingen, 72076, Germany.
Katrin BenzlerDepartment of Medical Oncology and Pneumology, University Hospital Tuebingen, Otfried-Mueller-Straße 10, Tuebingen, 72076, Germany.
Lars ZenderDepartment of Medical Oncology and Pneumology, University Hospital Tuebingen, Otfried-Mueller-Straße 10, Tuebingen, 72076, Germany.
Adrien DaigelerDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tuebingen, University of Tuebingen, Schnarrenbergstraße 95, Tuebingen, 72076, Germany.
Johannes Tobias ThielDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tuebingen, University of Tuebingen, Schnarrenbergstraße 95, Tuebingen, 72076, Germany. JThiel@bgu-tuebingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the tolerability of multimodal therapy in soft tissue sarcoma patients, particularly with regard to their quality of life and level of distress. MATERIALS AND

methodsA retrospective cohort study enrolled individuals receiving sarcoma therapy at the sarcoma center of the University of Tuebingen between 2017 and 2022. Participants completed an online survey that included the EORTC's questionnaire (QLQ-C30), coupled with the distress thermometer and demographic inquiries. The primary emphasis was on comparing three distinct modalities: Radiation, Chemotherapy and Surgery. The data were analysed performing one-way ANOVA.

resultsA total of 237 patients were included in the study. There was a significant difference (p < 0.001) in quality of life according to the EORTC scores (high score = high quality of life) between the different treatments: chemotherapy (mean: 26.8 [standard deviation: 19.5]), radiotherapy (51.0 [21.5]), and surgery (46.9 [28.3]). Similarly, a statistically significant discrepancy (p < 0.001) was found in average distress levels (high score = high level of distress) corresponding to each treatment type: radiation (5.0 [2.7]), surgery (6.0 [2.9]), and chemotherapy (7.4 [2.4]). The rates of patients willing to undergo the same treatment varied across groups, with the highest percentage observed in the surgery group (94.2%), followed by radiation (87.4%), and chemotherapy (73.5%).

conclusionPatients receiving multimodal therapy for soft tissue often find chemotherapy particularly demanding. Impairment of both quality of life and physical well-being is more likely and tends to be more severe compared with radiation or surgery. These observations should be taken into consideration when consenting patients and offering treatment plans.

Indexed as

Quality of LifeSarcomaAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurveys and QuestionnairesYoung AdultEORTCPatient Reported Outcomes (PROs)Quality of lifeSarcomaSarcoma therapySarkoLife

Identifiers

PMID39773479
PMCPMC11708100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.